Navigation Links
Sinovac to Present at 55th Annual BioPharma China Convention 2012 - Vaccine & Antibody Focus
Date:6/18/2012

BEIJING, June 18, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that management is scheduled to present at the 5th Annual BioPharma China Convention 2012, to be held June 20 and 21 at the Beijing Marriot Hotel Northeast in Beijing, China. Bringing together more than 300 global biopharmaceutical professionals, the 2012 convention will focus on opportunities for greater achievements in novel vaccines and monoclonal antibody (mAb) drugs.

Ms. Helen Yang, Sinovac's Director of International Business Development & Investor Relations, will deliver a presentation entitled, "Keeping Abreast with Global Vaccine Frontiers & Providing High Quality Vaccines to the World", on June 21, 2012.

Ms. Yang participated at the 3rd International Roundtable on China-Africa Health Collaboration on June 12, 2012.  The conference, organized by the Institute for Global Health, Peking University, bought together the Chinese Ministry of Commerce, the Chinese Ministry of Health, international health organizations, and African officials to strengthen communication, and discuss issues and solutions related to collaboration, between the two countries. Ms. Yang delivered a presentation entitled, "Environmental Prerequisites to Investing in the Pharmaceutical Sector in Developing Countries", that aimed to raise Sinovac's profile across the international healthcare industry, attract potential partners for international markets, and showcase its international strategy to key government and partnering constituencies.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu) and H1N1 influenza (swine flu), as well as animal rabies vaccine for canines. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, Panflu.1, and has manufactured it for the Chinese Central Government, pursuant to the government-stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government-stockpiling program. Sinovac is developing a number of new pipeline vaccines including vaccines for Enterovirus71 (against hand, foot and mouth disease), pneumococcal conjugate, pneumococcal polysaccharides, mumps and rubella. Sinovac sells its vaccines mainly in China and exports selected vaccines to Mongolia, Nepal, and the Philippines.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For further information, please contact:

Helen Yang/Chris Lee
Sinovac Biotech Ltd.
Tel:  +86-10-8279-9871/9659
Fax:  +86-10-6296-6910
Email: ir@sinovac.com

Investors:

Stephanie Carrington
The Ruth Group
Tel:  +1-646-536-7017
Email: scarrington@theruthgroup.com

Media

Victoria Aguiar
The Ruth Group
Tel:  +1-646-536-7013
Email: vaguiar@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac Announces Resignation of Chup Hung Mok from Board of Directors
2. NYSE Companies and NASDAQ Companies June 7th Investor Presentations Now Available at RetailInvestorConferences.com
3. Fusion presents low proliferation risk, experts conclude
4. Discovery Labs to Present AFECTAIR® Data at European Congress on Pediatric and Neonatal Ventilation
5. Luminex Corporation to Present at Jefferies 2012 Global Healthcare Conference
6. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
7. Watson to Present at Goldman Sachs Global Healthcare Conference 2012
8. Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
9. Exosome Diagnostics Presents Data at American Urology Association Demonstrating Potential Utility of Urine Exosomes to Non-invasively Detect and Manage Prostate Cancer
10. PAREXEL International To Present At Goldman Sachs Healthcare Conference And Jefferies Healthcare Conference
11. ETEX Corporation to present at the 9th World Biomaterial Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... -- Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual property development ... property, today provided an update on the Company,s cases ... Texas and announcing that those ... Re-examination ("IPR") proceedings that VTech and Uniden filed ... on only certain claims of two of the patents ...
(Date:2/3/2016)... Feb. 3, 2016   ViaCyte, Inc ., ... first pluripotent stem cell-derived islet replacement therapy for ... development, today announced that ViaCyte and Janssen Biotech, ... Johnson & Johnson, have agreed to consolidate the ... The agreement provides ViaCyte with an exclusive license ...
(Date:2/3/2016)... , Feb. 3, 2016 New ... more than $1 million for researchers in ... on health-related research that demonstrates exciting potential.   ... of funding for the New Jersey Health Foundation Research ... members at these educational institutions— Princeton University, Rutgers ...
(Date:2/3/2016)... -- Silk Therapeutics, Inc., today announced the closing of a $6 ... a total of $10.25 million in Series A funding based ... round was led by existing investor The Kraft Group of ... investors Lear Corporation and Highland Consumer Partners, as well as ... Richard Sackler , MD, with Summer Road, LLC; Erin ...
Breaking Biology Technology:
(Date:2/3/2016)... , February 4, 2016 --> ... to SEK 1,351.5 M (105.0), up 1,187% compared with fourth quarter of ... amounted to SEK 517.6 M (loss: 30.0). Earnings per share ... activities was SEK 537.4 M (neg: 74.7). , ... , Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% compared with ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 /PRNewswire/ ... facilities are primarily focused on medical screening ... measure point-of-care parameters. Wearable devices that facilitate ... user,s freedom of movement are being bolstered ... for human biomedical signal acquisition coupled with ...
(Date:2/2/2016)... 2016   Parabon NanoLabs (Parabon) announced ... Research Office and the Defense Forensics and Biometrics ... the company,s Snapshot Kinship Inference software ... generally, defense-related DNA forensics.  Although Snapshot is best ... and ancestry from DNA evidence), it also has ...
Breaking Biology News(10 mins):